Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × ravulizumab × 30 days × Clear all

Phase

Phase 4 1 Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1 Adrenal Insufficiency 1

Interventions

Prednisone 3 Carboplatin 3 enzalutamide 2 Injections 2 HMPL-013 2 Dexamethasone 2 Cisplatin 2 Cannabidiol 2 zanubrutinib 1 trastuzumab deruxtecan 1 trastuzumab biosimilar HLX02 1 toripalimab 1 testosterone 17 beta-cypionate 1 talquetamab 1 suvorexant 1 sofosbuvir-velpatasvir drug combination 1 ruxolitinib 1 rozanolixizumab 1 ribociclib 1 relatlimab 1 ravulizumab 1 pirtobrutinib 1 pembrolizumab 1 obinutuzumab 1 nirogacestat 1 niraparib 1 nilotinib 1 lenvatinib 1 ibrutinib 1 human papillomavirus vaccine, L1 type 16, 18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07221838 2026-03-03

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Not yet recruiting

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡